Trial Profile
Phase Ib Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Mipetresgene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Bladder cancer; Liver cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Solid tumours; Synovial sarcoma
- Focus Adverse reactions
- 06 Dec 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 06 Dec 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 08 Jan 2023 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.